Optimus Holding Successfully Completes Acquisition of OM Pharma

Published on: 

Optimus Holding has successfully completed the acquisition of OM Pharma.

Swiss group, Optimus Holding, has successfully completed the acquisition of global biotech company based in Geneva, OM Pharma. The acquisition was announced in a Sept. 30, 2020 press release.

The new owners have committed to investing more than CHF 250 million (US $272 million) in the development of microbial-derived immunotherapeutics against respiratory diseases and inflammation, among other projects. Additionally, OM Pharma’s manufacturing capacity in Meyrin, Geneva, will be expanded, with the expansion project expected to commence later in 2020.

“Together with my long-standing and experienced partners, I am excited to further expand OM Pharma and create a highly attractive biotechnology company focused on improving the lives of patients with respiratory and inflammatory diseases. We will also strengthen the already important biotech cluster in Switzerland,” said Etienne Jornod, founder of Optimus Holding and executive chairman of OM Pharma, in the press release. “Our aim is to invest in people, deepen R&D, leverage production, and expand commercial activities in and outside of Switzerland.”


Josef Troxler, CEO of OM Pharma, added, in the press release, “Thanks to the new owners, OM Pharma is well positioned to become a world-leading biotech company focused on respiratory diseases and inflammation. We have the intent to develop OM Pharma's activities in the Geneva region by attracting and retaining the best talents, building on the company’s strengths, and combining the skills of the management team with the expertise and know-how of the new owners. We will expand geographically, in the US [United States] and particularly in China, where we have just signed a collaboration agreement with AstraZeneca. With Abdi Ibrahim, the largest independent Turkish pharma company, as our strategic partner, we will further grow our presence in other markets, especially in the MENA [Middle East and North Africa] region.”

Source: OM Pharma